StreetInsider.com News Articles

Form SCHEDULE 13G/A KAZIA THERAPEUTICS LTD Filed by: Dauntless Investment Group, LLC

Fri, 02 Oct 2026 15:57:00 -0400

si-local-file:///var/storage/secattach/20261002/27141916.html

Form EFFECT Kazia Therapeutics Limit

Mon, 28 Sep 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260928/27109638.html

Form 424B3 KAZIA THERAPEUTICS LTD

Tue, 22 Sep 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260922/27087982.html

Form 424B3 KAZIA THERAPEUTICS LTD

Tue, 22 Sep 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260922/27087956.html

Form 424B3 KAZIA THERAPEUTICS LTD

Tue, 22 Sep 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260922/27087971.html

Form 424B3 KAZIA THERAPEUTICS LTD

Tue, 22 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260922/27087918.html

Form 6-K KAZIA THERAPEUTICS LTD For: Sep 22

Tue, 22 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260922/27087861.html

Sovargen doses first patient in paxalisib epilepsy trial, triggering $2M payment

Tue, 22 Sep 2026 07:30:33 -0400

Sovargen Co., Ltd. has dosed the first patient in a Phase 1b/2a clinical trial evaluating paxalisib for the treatment of intractable epilepsy associated with focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC), triggering a $2 million milestone payment to Kazia Therapeutics Limited (NASDAQ: KZIA) under the companies' exclusive licensing agreement.

The trial targets rare, genetically driven neurological disorders in which mutations in the PI3K/Akt/mTOR pathway drive treatment-resistant seizures. There are currently no approved therapies for FCD T2. Paxalisib is an oral, brain-penetrant dual inhibitor of PI3K and mTOR.

Kazia and Sovargen entered their licensing agreement in March 2024,

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Tue, 22 Sep 2026 07:30:00 -0400

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia

SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd., a biotechnology

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Tue, 22 Sep 2026 07:30:00 -0400

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia

Form 424B3 KAZIA THERAPEUTICS LTD

Fri, 18 Sep 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260918/27080494.html

Form 424B3 KAZIA THERAPEUTICS LTD

Fri, 18 Sep 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260918/27080481.html

Form 424B3 KAZIA THERAPEUTICS LTD

Fri, 18 Sep 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260918/27080488.html

Form 424B3 KAZIA THERAPEUTICS LTD

Fri, 18 Sep 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260918/27080491.html

Form 6-K KAZIA THERAPEUTICS LTD For: Sep 18

Fri, 18 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260918/27080467.html

Form F-6 Kazia Therapeutics Limit Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary

Fri, 18 Sep 2026 09:55:00 -0400

si-local-file:///var/storage/secattach/20260918/27078971.html

Kazia Therapeutics doses first patient in AT/RT brain cancer trial

Wed, 09 Sep 2026 07:33:11 -0400

Kazia Therapeutics (NASDAQ: KZIA) announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib in combination with gemcitabine for patients ages 1 to 39 with recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), a form of pediatric brain cancer.

The study is conducted by the Pediatric Neuro-Oncology Consortium (PNOC) and is an open-label, multi-center platform trial. In Arm A, patients receive oral, once-daily paxalisib alongside intravenous gemcitabine on Days 1, 8, and 15 of each 28-day treatment cycle.

Paxalisib holds both Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food

Kazia Therapeutics (KZIA) PT Raised to $40 at BTIG

Tue, 01 Sep 2026 10:17:11 -0400

BTIG analyst Kambiz Yazdi raised the price target on Kazia Therapeutics (NASDAQ: KZIA) to $40.00 (from $34.00) while maintaining a Buy rating.

The analyst comments "Paxalisib showed an 83% ORR and 100% CBR across six evaluable metastatic TNBC patients, including one complete response and activity across multiple metastatic sites, including CNS lesions. While the sample size is small, the breadth of activity and biomarker data are notable, with all six patients showing reductions in terminally exhausted CD8+ T cells and CTC clusters, supporting both PI3K pathway engagement and a possible immune-restorative effect. Kazia reported no paxalisib-related serious adverse events and no

Kazia Therapeutics (KZIA) PT Raised to $40 at BTIG

Tue, 01 Sep 2026 10:17:11 -0400

BTIG analyst Kambiz Yazdi raised the price target on Kazia Therapeutics (NASDAQ: KZIA) to $40.00 (from $34.00) while maintaining a Buy rating.

Kazia reports paxalisib data in colorectal cancer, plans Phase 2 trial

Tue, 01 Sep 2026 07:33:54 -0400

Kazia Therapeutics (NASDAQ: KZIA) announced preclinical data showing its drug paxalisib reduced tumor burden by 52% in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer models, according to a company statement.

In a separate preclinical study, adding paxalisib to pembrolizumab, an existing immunotherapy drug, reduced tumor volume by an additional 50% compared with pembrolizumab alone. The company reported no evidence of treatment-related toxicity across both studies.

MSS/pMMR colorectal cancer accounts for approximately 85–90% of metastatic colorectal cancer cases. Published clinical data indicate that checkpoint inhibitor monotherapy has provided little to no clinical benefit in this patient population.

Kazia is also developing

Kazia reports paxalisib data in colorectal cancer, plans Phase 2 trial

Tue, 01 Sep 2026 07:33:54 -0400

Kazia is also developing

Kazia reports paxalisib data in colorectal cancer, plans Phase 2 trial

Tue, 01 Sep 2026 07:33:54 -0400

Kazia is also developing

Kazia reports paxalisib data in colorectal cancer, plans Phase 2 trial

Tue, 01 Sep 2026 07:33:54 -0400

Kazia is also developing

Kazia prices public offering at $15.50 per ADS, eyes $40M in proceeds

Fri, 28 Aug 2026 07:30:18 -0400

Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.

The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up

Kazia prices public offering at $15.50 per ADS, eyes $40M in proceeds

Fri, 28 Aug 2026 07:30:18 -0400